NuvOx Closed Oversubscribed Convertible Notes

NuvOx Announces Publication of Research Article in Cancer Research Communication
NuvOx Announces BARDA Partnership for a Phase Ib ARDS/COVID Trial in Canada
NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
NuvOx Receives SPAN Grant

NuvOx Newly Issued US Patent
NuvOx Pharma Announces Issuance of a New Patent
NuvOx Appoints Dr. Robert King to SAB
NuvOx Technology Featured in Prominent Peer Review Journal
NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials
NuvOx Receives Notice from the Breakthrough DOD Award for its Immuno-Oncology Program
NuvOx to Participate in the BIO CEO Investor Conference
NuvOx to Present at Various Bio Forums in JPM Week Tucson, AZ, January 7, 2022
NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke
NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy
NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM
NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer


Tucson's NuvOx adds plant to make drugs in-house
NuvOx Completes Construction of Expanded Manufacturing Facility
NuvOx Pharma Announces Appointment of Jon S. Saxe to Its Board of Directors


Hunniwell Lake Ventures Spotlights NuvOx

Health Canada Allows Phase IIa Clinical Trial in COVID-19 Patients with Respiratory Failure

NuvOx Expands Production Line

NuvOx Pharma’s NanO2 Shows Positive Results in Phase Ib/II Stroke Trial


NuvOx Wins TechConnect Defense Innovation Award


NuvOx Pharma wins AZBio Fast Lane Award

National Cancer Institute Grants $3M to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer

NuvOx Wins MedCity INVEST Perfect Pitch Contest

NuvOx wins Venture Madness competition and $60,000 prize.